199 related articles for article (PubMed ID: 35997890)
1. Role of baseline
Telli TA; Ozguven S; Alan O; Filizoglu N; Ozturk MA; Sariyar N; Isik S; Arikan R; Demircan NC; Basoglu T; Cetin IA; Ones T; Ercelep O; Dane F; Yumuk PF
Ann Nucl Med; 2022 Nov; 36(11):964-975. PubMed ID: 35997890
[TBL] [Abstract][Full Text] [Related]
2. Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of
Zou Q; Jiao J; Zou MH; Li MZ; Yang T; Xu L; Zhang Y
Abdom Radiol (NY); 2020 Dec; 45(12):4202-4213. PubMed ID: 32948911
[TBL] [Abstract][Full Text] [Related]
3. Response assessment using
Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
[TBL] [Abstract][Full Text] [Related]
4. mCRPC Patients Receiving
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Mdlophane A; Maes A; Mokoala K; Mathabe K; Van C; Wiele D; Morgenstern A
J Nucl Med; 2022 Oct; 63(10):1496-1502. PubMed ID: 35177427
[No Abstract] [Full Text] [Related]
5. Pre-treatment
Eisazadeh R; Mirshahvalad SA; Schwieghofer-Zwink G; Hehenwarter L; Rendl G; Gampenrieder S; Greil R; Pirich C; Beheshti M
Mol Imaging Biol; 2024 Apr; 26(2):360-369. PubMed ID: 38360991
[TBL] [Abstract][Full Text] [Related]
6. Early molecular imaging response assessment based on determination of total viable tumor burden in [
Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
[TBL] [Abstract][Full Text] [Related]
7.
Shagera QA; Artigas C; Karfis I; Critchi G; Chanza NM; Sideris S; Peltier A; Paesmans M; Gil T; Flamen P
J Nucl Med; 2022 Aug; 63(8):1191-1198. PubMed ID: 34772793
[TBL] [Abstract][Full Text] [Related]
8. Determination of whole-body tumour burden on [68Ga]PSMA-11 PET/CT for response assessment of [177Lu]PSMA-617 radioligand therapy: a retrospective analysis of serum PSA level and imaging derived parameters before and after two cycles of therapy.
Michalski K; Mix M; Meyer PT; Ruf J
Nuklearmedizin; 2019 Dec; 58(6):443-450. PubMed ID: 31724145
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients.
Özülker T; Özülker F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(5):292-298. PubMed ID: 32595026
[TBL] [Abstract][Full Text] [Related]
10. Role of volumetric parameters obtained from
Güzel Y; Kömek H; Can C; Kaplan İ; Akdeniz N; Kepenek F; Gündoğan C
Ann Nucl Med; 2023 Sep; 37(9):517-527. PubMed ID: 37332068
[TBL] [Abstract][Full Text] [Related]
11. Development of a Visually Calculated SUV
Swiha M; Papa N; Sabahi Z; Ayati N; John N; Pathmanandavel S; Crumbaker M; Li S; Agrawal S; Ayers M; Hickey A; Sharma S; Nguyen A; Emmett L
J Nucl Med; 2024 Jun; 65(6):904-908. PubMed ID: 38637137
[No Abstract] [Full Text] [Related]
12. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Performance of RECIP 1.0 Based on [
Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Higuchi T; Schlötelburg W; Michalski K; Gafita A; Rowe SP; Pomper MG; Buck AK; Werner RA
J Nucl Med; 2024 Apr; 65(4):560-565. PubMed ID: 38453363
[TBL] [Abstract][Full Text] [Related]
14. Response assessment using [
Grubmüller B; Rasul S; Baltzer P; Fajkovic H; D'Andrea D; Berndl F; Maj-Hes A; Grubmüller KH; Mitterhauser M; Wadsak W; Pfaff S; Shariat SF; Hacker M; Kramer G; Hartenbach M
Prostate; 2020 Jan; 80(1):74-82. PubMed ID: 31614001
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy, prognostic variables and clinical outcome of
Suman S; Parghane RV; Joshi A; Prabhash K; Bakshi G; Talole S; Banerjee S; Basu S
Br J Radiol; 2019 Dec; 92(1104):20190380. PubMed ID: 31600089
[TBL] [Abstract][Full Text] [Related]
16. Change in total lesion PSMA (TLP) during [
Burgard C; Hein C; Blickle A; Bartholomä M; Maus S; Petto S; Schaefer-Schuler A; Ezziddin S; Rosar F
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):885-895. PubMed ID: 37889298
[TBL] [Abstract][Full Text] [Related]
17. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
[TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
19. PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors.
Shagera QA; Karfis I; Kristanto P; Spyridon S; Diamand R; Santapau A; Peltier A; Roumeguère T; Flamen P; Artigas C
J Nucl Med; 2023 Dec; 64(12):1869-1875. PubMed ID: 37770114
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
